Schwab Charles Investment Management Inc. increased its stake in Omeros Co. (NASDAQ:OMER) by 10.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 217,804 shares of the biopharmaceutical company’s stock after acquiring an additional 20,139 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.45% of Omeros worth $4,709,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wells Fargo & Company MN raised its holdings in Omeros by 13.8% in the third quarter. Wells Fargo & Company MN now owns 42,144 shares of the biopharmaceutical company’s stock valued at $911,000 after buying an additional 5,102 shares during the period. First Interstate Bank purchased a new position in Omeros in the third quarter valued at approximately $108,000. EAM Investors LLC raised its holdings in Omeros by 30.4% in the third quarter. EAM Investors LLC now owns 202,025 shares of the biopharmaceutical company’s stock valued at $4,368,000 after buying an additional 47,146 shares during the period. SG Americas Securities LLC raised its holdings in Omeros by 138.9% in the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 7,067 shares during the period. Finally, Hanseatic Management Services Inc. raised its holdings in Omeros by 10,919.6% in the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 10,592 shares during the period. 49.71% of the stock is currently owned by institutional investors and hedge funds.
OMER has been the topic of several research reports. HC Wainwright set a $30.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Thursday, December 14th. Maxim Group set a $24.00 price target on shares of Omeros and gave the company a “buy” rating in a report on Tuesday, December 12th. Zacks Investment Research lowered shares of Omeros from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, Cowen lowered shares of Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Omeros has a consensus rating of “Buy” and an average target price of $34.14.
Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. The firm had revenue of $21.66 million for the quarter, compared to analysts’ expectations of $17.82 million. The company’s revenue for the quarter was up 91.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.34) EPS. sell-side analysts forecast that Omeros Co. will post -0.98 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Omeros Co. (OMER) Shares Bought by Schwab Charles Investment Management Inc.” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://weekherald.com/2018/01/11/omeros-co-omer-shares-bought-by-schwab-charles-investment-management-inc.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.